HOUSTON, July 24 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX - News) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the company’s proposal to amend the protocol of its D-21 post-approval dosing study in depression patients treated with VNS Therapy(TM).
